"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...